Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study

Eric J. Haas(Israel Ministry of Health), Sharon Alroy‐Preis(Israel Ministry of Health), Meir Smaja(Israel Ministry of Health), Gabriel Mircus, Jo Southern(Pfizer (United States)), Kaijie Pan(Pfizer (United States)), Luis Jódar(Pfizer (United States)), Farid Khan(Pfizer (United States)), Nati Brooks(Israel Ministry of Health), David L. Swerdlow(Pfizer (United States)), Shepherd Roee Singer(Hebrew University of Jerusalem), Yeheskel Levy(Israel Ministry of Health), John M. McLaughlin(Pfizer (United States)), Frederick J. Angulo(Pfizer (United States)), Emilia Anis(Israel Ministry of Health), Marc Lipsitch(Harvard University)
The Lancet Infectious Diseases
September 22, 2021
10.1016/s1473-3099(21)00566-1
Cited by 134

Related Papers

Foodborne Illness Acquired in the United States—Major Pathogens
|Emerging infectious diseases|2010|7.6k
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
|The Lancet|2021|1.7k
Hospitalized Patients with 2009 H1N1 Influenza in the United States, April–June 2009
|New England Journal of Medicine|2009|1.7k
H1N1 2009 influenza virus infection during pregnancy in the USA
|The Lancet|2009|1.4k
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
|The Lancet|2021|1.3k